Vator Securities acted as Sole Bookrunner and Advisor in connection with the transaction raising SEK 60 million.
Ascelia Pharma is a Swedish-based specialty oncology drug development company with a late stage pipeline of products with potential to significantly improve survival in cancer patients. The lead asset Mangoral® is a novel MR imaging (MRI) drug, which is being developed for detection of liver metastases in patients with severely impaired kidney function who are at risk of serious side effects if given any of the current imaging drugs on the market. Today, these patients have no safe and effective imaging drug to improve the detection of liver metastases. Mangoral® will fill the gap for this patient segment and potentially improve their survival rate. The market size for this patient segment is estimated to USD 350-500 million. Mangoral® has Orphan Drug Designation from FDA and is ready for Phase III, with estimated completion in H1-2021.
The second product candidate Oncoral is a novel chemotherapy tablet for the treatment of gastric cancer – a market estimated at USD 3.5 billion in 2020. Oncoral is currently in Phase I, with estimated completion in 2018. Ascelia Pharma is backed by a wide and well-renowned group of shareholders, Key Opinion Leaders and advisors. Ascelia Pharma is preparing for a main market listing on Nasdaq Stockholm in Q1 2019.
The proceeds from the equity issuance will primarily be used to finalize preparations for the Mangoral® Phase III clinical study as well as complete the ongoing Oncoral Phase I study.
For further information,
Homan Panahi, CEO, Vator Securities
Tel: +46 763-98 96 66
About Vator Securities
Vator Securities provides an extensive range of capital markets and advisory services to cutting-edge public and private growth companies with an emphasis on the Life Sciences, Medical Technology and Diagnostics industries. Vator Securities executes on opportunities that accelerate growth for its client companies while delivering results to the firm’s sophisticated investor clientele. Vator Securities distinguishes itself by the firm’s ability to raise capital from traditional institutional investors, as well as from its proprietary global network of family office and high net worth investors. Vator Securities was founded in Stockholm in 2009 and the firm is primarily an equity partnership.